Wolfe Research Initiates Coverage On Nyxoah with Peer Perform Rating, Announces Price Target of $21
Wolfe Research analyst Mike Polark initiates coverage on Nyxoah (NASDAQ:NYXH) with a Peer Perform rating and announces Price Target of $21.
Earnings Scheduled For March 24, 2022
Companies Reporting Before The Bell
• iHuman (NYSE:IH) is likely to report earnings for its fourth quarter.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 35 companies made new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning session, 34 stocks hit new 52-week lows.
Nyxoah’s Sleep Apnea Device Receives FDA Breakthrough Tag
The FDA has granted Breakthrough Device Designation to Nyxoah SA (NASDAQ:NYXH) Genio bilateral hypoglossal nerve stimulation system. The…
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen’s Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 13)
Nyxoah Announces Pricing Of Public Offering Of 2.835M Shares At $30/Share
Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA),
This Week’s Scheduled IPOs
With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.